WA
GSK icon

Walsh & Associates’s GSK GSK Stock Holding History

Walsh & Associates’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.19K Hold
80
– – ﹤0.01% 215
2026
Q1 		$4.42K Hold
80
– – ﹤0.01% 200
2025
Q4 		$3.92K Buy
+80
New +$3.73K ﹤0.01% 206

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Walsh & Associates's GSK Position: Q2 2026 in Review

Walsh & Associates held its GSK (GSK) position steady in Q2 2026 at 80 shares worth $4.19K. The position accounts for ﹤0.01% of the portfolio, ranked #215.

Walsh & Associates first reported a position in GSK in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.42K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Walsh & Associates held 80 shares of GSK worth $4.19K as of Q2 2026.
  • Walsh & Associates left its GSK share count unchanged in Q2 2026.
  • GSK made up ﹤0.01% of Walsh & Associates's portfolio in Q2 2026, its #215 holding.
  • Walsh & Associates first reported a position in GSK in Q4 2025 and has held it in 3 quarters since.
  • Walsh & Associates's GSK position peaked at $4.42K in Q1 2026.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Walsh & Associates's 13F filing for Q2 2026, filed 21 Jul 2026.